{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Graziadei G"],"pubmed_abstract":["Sickle cell disease (SCD) is a worldwide distributed hereditary red cell disorder characterized by recurrent acute vaso-occlusive crises (VOCs and anemia). Gold standard treatments are hydroxycarbamide (HC) and/or different red blood cell (RBC) transfusion regimens to limit disease progression. Here, we report a retrospective study on 1,579 SCD patients (median age 23 years; 802 males/777 females), referring to 34 comprehensive Italian centers for hemoglobinopathies. Although we observed a similar proportion of Caucasian (47.9%) and African (48.7%) patients, Italian SCD patients clustered into two distinct overall groups: children of African descent and adults of Caucasian descent. We found a subset of SCD patients requiring more intensive therapy with a combination of HC plus chronic tran"],"journal":["Frontiers in medicine"],"pagination":["832154"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8967327"],"repository":["biostudies-literature"],"pubmed_title":["Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy."],"pmcid":["PMC8967327"],"pubmed_authors":["Casale M","Palazzi G","Macchi S","Rossi E","Russo G","Di Maggio R","Lisi R","Filosa A","Voi V","De Franceschi L","Bonetti F","Piperno A","Forni GL","Facchini E","Colombatti R","Giona F","Badalamenti L","Arcioni F","Vassanelli A","Maroni P","Giordano P","Graziadei G","Sau A","Marktel S","Murgia M","Masera N","Venturelli D","Origa R","Bortolotti M","Corti P","Bonomo P","Mariani R","Colarusso G","Gianesin B","Quota A","Notarangelo LD","Campisi S","Pinto VM","Lodi G","Allo M","Rosso R","Boscarol G","Longo F","D'Ascola D","Fidone C","Piel FB","Sainati L","Rigano P"],"additional_accession":[]},"is_claimable":false,"name":"Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy.","description":"Sickle cell disease (SCD) is a worldwide distributed hereditary red cell disorder characterized by recurrent acute vaso-occlusive crises (VOCs and anemia). Gold standard treatments are hydroxycarbamide (HC) and/or different red blood cell (RBC) transfusion regimens to limit disease progression. Here, we report a retrospective study on 1,579 SCD patients (median age 23 years; 802 males/777 females), referring to 34 comprehensive Italian centers for hemoglobinopathies. Although we observed a similar proportion of Caucasian (47.9%) and African (48.7%) patients, Italian SCD patients clustered into two distinct overall groups: children of African descent and adults of Caucasian descent. We found a subset of SCD patients requiring more intensive therapy with a combination of HC plus chronic tran","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-04-08T18:11:01.955Z","creation":"2025-04-05T22:19:50.994Z"},"accession":"S-EPMC8967327","cross_references":{"pubmed":["35372393"],"doi":["10.3389/fmed.2022.832154"]}}